Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on October 30, 2014. The filing serves to announce the Company's financial results for the third quarter of 2014. The registrant is incorporated in Delaware and maintains its principal executive offices in Bothell, Washington.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the body of this 8-K document.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the third-quarter 2014 results.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The information regarding the financial results is furnished and explicitly stated as not being "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are absent from the 8-K text.
- Verify the Company's name discrepancy: The filing metadata lists "ACHIEVE LIFE SCIENCES, INC.", but the document header and signature block identify the registrant as OncoGenex Pharmaceuticals, Inc.
- Confirm the status of the financial data as "furnished" rather than "filed," which affects its legal standing for incorporation by reference.